• Kaleido ends oversubscribed funding round at $101m pharmaceutical-technology
    June 28, 2018
    Microbiome startup Kaleido Biosciences has closed its oversubscribed Series C financing round at $101m. Investment came from Fidelity Management, Invus, as well as a subsidiary of Abu Dhabi Investment Company and Flagship Pioneering, Kaleido’s founder.
PharmaSources Customer Service